Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma

Immune checkpoint blockade (ICB) therapies that target programmed cell death 1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Mingming, Yao, Linli, Yang, Qin, Chi, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046689/
https://www.ncbi.nlm.nih.gov/pubmed/32154170
http://dx.doi.org/10.3389/fonc.2020.00168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046689/
https://www.ncbi.nlm.nih.gov/pubmed/32154170
http://dx.doi.org/10.3389/fonc.2020.00168

Ejemplares similares